- Ambitions (yes, we’re ambitious …)
-
This very first page is a good place to mention our ambitions here at the Division of Medicinal Chemistry of Leiden University. We want to understand drug action at ‘high resolution’, thus at an almost atomic level. We want to use that understanding for a more rational approach of drug design. We have chosen the most important class of drug targets to work on, the G protein-coupled receptors (GPCRs). Close to half of all medicines work via these targets in our body.
Well, one can’t study all receptors, as there are over 800 of them in the human body. So, we have selected a few to concentrate on, receptors for adenosine, for nicotinic acid, and receptors that are vital for reproduction. We pursue a ‘chemical biology’ approach, in which we combine synthetic chemistry, new developments in the world of informatics and computer science (bioinformatics, cheminformatics), and both biochemistry and pharmacology. That is quite ideal, as we now have in one hand all ingredients to come up with ideas for new drugs, make them, and see how they work.
Why don’t you read more about the fascinating four adenosine receptors? One may help to cure Parkinson’s disease, most are involved in the actions of caffeine… - Read more
Introduction
Highlights
- Dong Guo Awarded Prize for ‘the most promising young professionals’ at the CALN pharmaceutical science seminar 2012
-
Dong Guo was awarded a prize for ‘the most promising young professionals’ from the CALN (the Chinese Association of Life-Science in the Netherlands) at the CALN pharmaceutical science seminar 2012 in Utrecht, the Netherlands, on April 21st.
- Read more
- Julia Hillger wins 2nd prize in the KNCV Golden Master Award 2011 competition
-
Julia Hillger was nominated for the KNCV Golden Master Award 2011 and won the 2nd prize for her scientific internship report 2011 at C2W career Expo 2012.
- Read more
- Laura Heitman and Ad IJzerman (LACDR) win Brussels €15 M bid for drug discovery
-
The European Union decided last week that out of 11 competing proposals the KINOTYPE consortium led by Laura Heitman and Ad IJzerman (LACDR, medicinal chemistry) won its bid for ‘optimizing binding kinetics’. This somewhat enigmatic title stands for a call in the Innovative Medicines program (IMI), worth €15 M, that aims at exploring a novel concept in modern drug discovery.
- Read more
- Julia Hillger awarded Suzanne Hovinga Prize
-
Julia Hillger was awarded the Suzanne Hovinga prize for the best scientific internship report 2011 at LACDR’s fall symposium in November.
- Read more







